Linkedin reporter Zoe Peterkin wrote up some questions she submitted to me and the file linked below is the full article. I think it will be useful as a concise outlining of Quietmind Foundation's experience providing neuroteedback combined with photobiomodulation (light therapy) to stop and reverse dementia symptoms. Our recruiting has started to work such that we now need only 20 more subjects for our study. Pleaase call 610-940-0488 for details. 
impacts-of-neurofeedback-therapy-on-neurodegenerative-disorders.pdf

Light exists on a spectrum. The human eye can only see a fraction of the existing natural light. Light therapy devices emit a low power near-infrared light (800nm - 1100nm) which is outside of the visible spectrum of human eyes but can still penetrate the human skin, skull, and brain. Infrared light is an essential component to Light Therapy because of its unique ability to both remedy chronic brain conditions and help maintain a healthy brain state. ​

Since 2007, we have worked to understand how PBM and light therapy can improve memory loss in people with memory loss or dementia. ​There are a number of devices available for light therapy use. At QuietMind, we use the 1070nm pulsed (40h) Cognitolite, QM/Neuronic 1070nm transcranial PBM system and 810nm and the Vielight Neuro alpha (10hz) and gamma (40hz) pulse rates. ​

​ 
Cognitolite was developed in the UK and studied by researchers at Durham University’s Department of Neuronal Physics. Quietmind has been studying this device for 13 years. The Cognitolite uses 1068nm pulsed infrared LEDs that covers the whole head and shines light into the eyes. Cognitolite uses 1100

​

Quietmind Foundation is recruiting subjects who are interested in joining a clinical trials using the Cognitolite device at home for 2 months.  ​

Quietmind Foundation has been providing integrative therapy that combines TPBM with home- based, brainwave biofeedback also called neurofeedback) training (NFB) that eliminates the underlying beta amyloid plaque while also increasing mitochondrial health and productivity with NFB to help repair our disrupted brain electrical networks independent of drug or other invasive procedures and unwanted side effects. QMF's longer-term therapy programs are conducted entirely at home by the patient and caregivers, with online training, clinical guidance, and periodic neuropsychiatric and neuropsychophsyiological evaluations at Quietmind Foundation's offices in Philadelphia, New York City, and Los Angeles. Please call Marvin Berman PhD at  610-940-0488 to be considered for one of our ongoing clinical trials or our longer-term comprehensive and individualized neurodegeneration treatment program.  ​

This article points at the fact that dysregulation of brain activity directly influences quality and lifespan itself. Overactivity is another way of describing dysregulated activity or in the parlance of neurotherapeutics, its inefficient brain activity. What we want as we age is to be more efficient in our movement and our thinking, this is what often is referred to as the 'wisdom of age'.  The work we do at QMF developing applications of digital neurotherapeutics(TM) is at its core, focused on enhancing neural efficiency and making sure we don't waste any of those little grey cells that Hercule Poirot depends on to solve the case. Our efforts are fixed on creating ways of noninvasively improving and maintaining optimal brain performance by maximizing neural efficiency.   

https://www.washingtonpost.com/science/2019/10/16/excessive-brain-activity-linked-shorter-life/

This paper suggests a novel and important aspect of the neurodegenerative process that needs to be better understood. We do know from studies at Durham University in the UK that 1065-1075nm light stimulation will enhance health and protect neurons from damage and thereby reduce the amount of fragments being created that may increase neural inflammation. Further research is needed to determine if the immune system is also enhanced in being able to remove these fragments more efficiently. Read about the study here: 
https://www.alzforum.org/news/research-news/mitochondrial-jetsam-spurs-neurodegeneration

Clinical trials at Quietmind Foundation using the 1065-1075nm pulsed infrared helmet are ongoing and people with diagnoses of early to mid-stage dementia are encouraged to contact Dr. Berman 610-940-0488 to discuss eligibility for the new home-based 60-day light therapy program.